1. National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
2. Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore, Singapore
3. Faculty of Science, National University of Singapore, Singapore, Singapore
4. Bioscience, Cardiovascular, Renal & Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
5. Department of Medicine (MedH), Integrated Cardio Metabolic Centre (ICMC), Heart and Vascular Theme, Karolinska Institute, Stockholm SE-171 77, Sweden
6. Early Clinical Development, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
7. Bioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
8. Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
9. Division of Cardiovascular Health and Disease, Department of Internal Medicine, Heart, Lung and Vascular Institute, University of Cincinnati, Cincinnati, OH, USA
10. Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
11. Health and Social Sciences Cluster, Singapore Institute of Technology, Singapore, Singapore
12. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
13. The Hatter Cardiovascular Institute, University College London, London, UK
14. Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taichung, Taiwan